OmniaBio Inc.
$35,950,000.00 CAD
- Program
- SIF Stream2- Growth
- Recipient country
- Canada
- Fiscal year
- 2025-2026
- Agreement period
- October 10, 2025 – July 31, 2047
- Reference
- ic:033-2025-2026-Q3-819843
Published purpose
This project will establish automated good manufacturing practice (GMP) facilities in Ontario to produce cell and gene therapy (CGT) products by integrating advanced robotics infrastructure and bioprocessing platforms supported by artificial intelligence.
In plain English AI-generated
This project funds the establishment of automated manufacturing facilities in Ontario to produce cell and gene therapy products using advanced robotics and AI-supported bioprocessing.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.